Lakewood-Amedex reports positive preclinical Bisphosphocin data

Lakewood-Amedex Biotherapeutics reported positive preclinical results for Bisphosphocin compounds in animal models of urinary tract, pulmonary infections. Rodent UTI testing showed Nu-8 reduced bacterial growth versus a vehicle control, supporting continued development in resistant infections. Aerosol formulations showed activity in pulmonary infection models, reinforcing potential positioning in hospital-acquired pneumonia and cystic fibrosis settings. Nu-3 remains the lead clinical program, with a Phase 2a trial in mildly infected diabetic foot ulcers underway. Topline Phase 2a data are expected in Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via (Ref. ID: 202610070802PR_NEWS_USPR_____NY64929) on October 07, 2026, and is solely responsible for the information contained therein. (C)